Meanwhile, the lesser nobles-a motley crew of coins-were galloping in wild and discordant ways: panic, surprise, triumph. What survived the tempest, and which vanished into the ether? Let us taste this week’s broth, sip a cup of bitter humor, and see what the market’s chronicler keeps in his ledger.
This wasn’t a little flutter, either. This purchase boosts Perceptive’s stake in Apogee to 3.14% of their overall holdings as of December 31st – a figure that sounds remarkably precise, doesn’t it? It suggests a degree of confidence, a belief that Apogee isn’t just a flash in the pan. They already held a decent amount, 2,330,651 shares to be exact, and the value of that position has swelled by $122.20 million, thanks to both the new investment and, crucially, the share price actually going up. A rare occurrence, that last bit.
Coca-Cola, of course, is the established name. The one everyone recognizes, the one with the history. It is a comfortable choice, like a well-worn armchair. But comfort, as one discovers, rarely translates to exceptional return. PepsiCo, perhaps, is the slightly overlooked sibling. Its yield, at 3.5%, is a modest offering, admittedly, but the market has already accounted for the sluggishness in its snack food division. It is a stock that asks for little, and may, in time, offer a little more than expected. One shouldn’t expect miracles, of course.
The divestment, documented in a recent SEC filing, represents a reduction in their Arcellx position by a not insignificant amount. The overall diminution of their stake, factoring in both sales and the inevitable ebb and flow of market valuations, totals a rather substantial $107.06 million. It is a cautionary tale, demonstrating that even the most sophisticated investors are susceptible to the whims of the market – and, perhaps, a touch of belated prudence.
The arithmetic is simple, yet telling. A complete exit, leaving Arohi with a stake of precisely 0% in this particular venture. It’s like a magician making a company disappear, only instead of a rabbit, it’s millions of dollars. Their current affections, if one can call them that, lie with GLBE ($148.60 million, a substantial 44.6% of their assets), SE ($144.38 million, or 43%), and a smattering of others – TEAM, AMZN, TOST – a portfolio diversified enough to withstand, perhaps, a slight digital apocalypse.
These are leveraged ETFs, and they operate on a principle that, while not exactly arcane, is best approached with a degree of cautious skepticism. You can find them offered by firms like Leverage Shares, Direxion, and ProShares. Historically, they’ve tended to latch onto broad market indices, like the S&P 500, offering products like the Direxion Daily S&P 500 Bull 3X Shares (SPXL +2.06%). Though, in a display of typical financial ingenuity, they’ve expanded to encompass sectors – ProShares Ultra Financials (UYG +1.41%) being a prime example – and, rather astonishingly, even individual stocks. There’s a 2X Long OPEN Daily ETF (OPEG +14.52%) tracking Opendoor Technologies, for goodness sake! They’ve even managed to create ETFs based on volatility itself – the 2x Long VIX Futures ETF (UVIX 4.53%) – which feels a bit like trying to bottle smoke.
The transaction, recorded on February 17th, 2026, involved the purchase of 4,415,514 shares. The total value of Redmile’s position in Nurix now represents a rather substantial 11.31% of their $1.358 billion in reported assets. One pictures the portfolio managers, meticulously arranging their holdings like specimens in a cabinet, occasionally daring to favour one over another. Their top five holdings, as of the filing, are as follows:
But the land is full of whispers, of catalysts that might yet lift XRP. The question isn’t if it could rise, but if the bargain price of $1.45 holds any real weight, or if it’s just another mirage in this sun-baked market.
Johnson & Johnson. JNJ. They’ve been handing out dividends for a long time. Over fifty years. That’s…a lot of years. They call them a Dividend King. Kings fall, of course. But this one seems pretty sturdy. So it goes.
According to the latest filings – those bureaucratic pronouncements that arrive with the regularity of a tax collector – Redmile increased its stake in Immunome during the fourth quarter of last year. The transaction, amounting to $12.20 million, swelled the total position by a substantial $64.01 million. A figure that includes not only the newly acquired shares, but also the capricious whims of the market. One must remember, the stock market is a fickle mistress, prone to sudden changes of heart.